Toshiyuki Ueki
Research Subjects
Toshiyuki Ueki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Yasushi Ikarashi
Tsumura Kampo Research Laboratories, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
4 shared publicationsKazushige Mizoguchi
Tsumura Kampo Research Laboratories, Kampo Research & Development Division, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
3 shared publicationsAkinori Nishi
Tsumura Research Laboratories, Kampo Scientific Strategies Division, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
2 shared publicationsHitomi Kanno
Tsumura Kampo Research Laboratories, Kampo Research & Development Division, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
2 shared publicationsKyoji Sekiguchi
Tsumura Research Laboratories, Kampo Scientific Strategies Division, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
2 shared publicationsYoshio Kase
Tsumura Research Laboratories, Kampo Scientific Strategies Division, Tsumura & Co., 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
2 shared publications
Latest Publications
- Open Access
- 1 November 2020
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 144 (3) , 129-138
Yokukansankachimpihange, a traditional Japanese (Kampo) medicine, enhances the adaptation to circadian rhythm disruption by increasing endogenous melatonin levels
- 1 November 2020
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 144 (3) , 129-138
Open AccessYokukansankachimpihange, a traditional Japanese (Kampo) medicine, enhances the adaptation to circadian rhythm disruption by increasing endogenous melatonin levels
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 6804017
Yokukansan, a Traditional Japanese Medicine, Enhances the Glutamate Transporter GLT‐1 Function in Cultured Rat Cortical Astrocytes
Astrocytes carry two glutamate transporters—GLAST and GLT‐1—the latter of which is responsible for >90% of glutamate uptake activity in the brain; however, under culture conditions, the GLT‐1 expression in astrocytes is exceedingly low, as is the glutamate uptake activity mediated by GLT‐1. This study aimed to elucidate the effects of yokukansan (YKS) in relation to the GLT‐1‐mediated regulation of extracellular glutamate concentrations. Thus, we treated cultured astrocytes with tumor necrosis factor‐α (TNF‐α) and dibutyryl‐cAMP (dBcAMP) (hereinafter, referred to as “TA”) to increase GLT‐1 expression and then functionally examined how YKS would affect glutamate uptake ability derived from GLT‐1. Contrary to expectations, although the TA treatments did not affect the uptake activity, YKS significantly augmented it. Conversely, GLAST‐derived glutamate uptake was significantly reduced by TA treatments but was unaffected by YKS. Subsequently, we analyzed the GLT‐1 protein and mRNA levels and found that TA treatments had significantly increased them, which were then further augmented by YKS. These findings suggest that YKS enhances GLT‐1‐derived glutamate transport functions in TA‐treated cultured astrocytes and that this process entails increased GLT‐1 protein and mRNA levels. This type of mechanism may contribute to the YKS‐mediated regulation of extracellular glutamate concentrations.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 6804017
Open AccessYokukansan, a Traditional Japanese Medicine, Enhances the Glutamate Transporter GLT‐1 Function in Cultured Rat Cortical Astrocytes
Astrocytes carry two glutamate transporters—GLAST and GLT‐1—the latter of which is responsible for >90% of glutamate uptake activity in the brain; however, under culture conditions, the GLT‐1 expression in astrocytes is exceedingly low, as is the glutamate uptake activity mediated by GLT‐1. This study aimed to elucidate the effects of yokukansan (YKS) in relation to the GLT‐1‐mediated regulation of extracellular glutamate concentrations. Thus, we treated cultured astrocytes with tumor necrosis factor‐α (TNF‐α) and dibutyryl‐cAMP (dBcAMP) (hereinafter, referred to as “TA”) to increase GLT‐1 expression and then functionally examined how YKS would affect glutamate uptake ability derived from GLT‐1. Contrary to expectations, although the TA treatments did not affect the uptake activity, YKS significantly augmented it. Conversely, GLAST‐derived glutamate uptake was significantly reduced by TA treatments but was unaffected by YKS. Subsequently, we analyzed the GLT‐1 protein and mRNA levels and found that TA treatments had significantly increased them, which were then further augmented by YKS. These findings suggest that YKS enhances GLT‐1‐derived glutamate transport functions in TA‐treated cultured astrocytes and that this process entails increased GLT‐1 protein and mRNA levels. This type of mechanism may contribute to the YKS‐mediated regulation of extracellular glutamate concentrations.
- 12 September 2012
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 33 (1) , 129-135
Effects of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook, a Constituent of Yokukansan, on Human Recombinant Serotonin7 Receptor
Effects of seven alkaloids, geissoschizine methyl ether (GM), hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine and isocorynoxeine, in Uncaria hook, a constituent of the kampo medicine yokukansan, on serotonin7 (5-HT7) receptor were investigated using Chinese hamster ovary (CHO) cell membranes and human embryonic kidney 293 (HEK293) cells stably expressing the human recombinant 5-HT7 receptor. A competitive binding assay using CHO membranes showed that GM (IC50 = 0.034 μM) more strongly inhibited the binding of the radioligand [3H] LSD to 5-HT7 receptor than the other alkaloids, suggesting that GM is bound to 5-HT7 receptor. Agonistic/antagonistic effects of GM (1–50 μM) on the receptor were evaluated by measuring intracellular cAMP levels in HEK239 cells. GM (IC50 = 6.0 μM) inhibited 5-HT-induced cAMP production in a concentration-dependent manner, as well as the specific 5-HT7 receptor antagonist SB-269970 (0.1–1 μM). However, GM did not induce intracellular cAMP production as 5-HT did. These results suggest that GM has an antagonistic effect on 5-HT7 receptor.
- 12 September 2012
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 33 (1) , 129-135
Effects of Geissoschizine Methyl Ether, an Indole Alkaloid in Uncaria Hook, a Constituent of Yokukansan, on Human Recombinant Serotonin7 Receptor
Effects of seven alkaloids, geissoschizine methyl ether (GM), hirsutine, hirsuteine, rhynchophylline, isorhynchophylline, corynoxeine and isocorynoxeine, in Uncaria hook, a constituent of the kampo medicine yokukansan, on serotonin7 (5-HT7) receptor were investigated using Chinese hamster ovary (CHO) cell membranes and human embryonic kidney 293 (HEK293) cells stably expressing the human recombinant 5-HT7 receptor. A competitive binding assay using CHO membranes showed that GM (IC50 = 0.034 μM) more strongly inhibited the binding of the radioligand [3H] LSD to 5-HT7 receptor than the other alkaloids, suggesting that GM is bound to 5-HT7 receptor. Agonistic/antagonistic effects of GM (1–50 μM) on the receptor were evaluated by measuring intracellular cAMP levels in HEK239 cells. GM (IC50 = 6.0 μM) inhibited 5-HT-induced cAMP production in a concentration-dependent manner, as well as the specific 5-HT7 receptor antagonist SB-269970 (0.1–1 μM). However, GM did not induce intracellular cAMP production as 5-HT did. These results suggest that GM has an antagonistic effect on 5-HT7 receptor.
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e226
Atypical antipsychotic-like effect of geissoschizine methyl ether on serotonin and dopamine receptors
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e226
Atypical antipsychotic-like effect of geissoschizine methyl ether on serotonin and dopamine receptors
- 28 August 2008
- Published by Wiley in Journal of Neuroscience Research
- Vol. 87 (2) , 503-513
A new monoclonal antibody, A3B10, specific for astrocyte‐lineage cells recognizes calmodulin‐regulated spectrin‐associated protein 1 (Camsap1)
Recent studies of adult neurogenesis of the mammalian central nervous system have suggested unexpected plasticity and complexity of neural cell ontogenesis. Redefinition and reconstitution of cell classification and lineage relationships, especially between glial and neural precursors, are an urgent and crucial concern. In the present study, we describe a new monoclonal antibody, A3B10, which was produced by immunizing mice with the membrane fraction prepared from astrocyte‐enriched primary neural cell cultures. Immunohistochemistry of brain sections, including brains from glial fibrillary acidic protein (GFAP)‐deficient mice and primary mixed neural cell cultures, as well as immunoblot analysis and immunoelectron microscopy, have revealed that 1) A3B10 recognizes a majority of cells in ependyma in neonatal and adult rats, 2) A3B10 stains almost all GFAP+ cells and some S100β+ cells in the corpus callosum, 3) A3B10 specifically stains astrocytes in vitro in primary cultures of rat embryonic cerebral hemispheres, 4) A3B10 equally stains ependymal cells of wild‐type and GFAP‐deficient mice, and 5) A3B10 antigen might construct intermediate filament bundles with GFAP and/or vimentin. These data suggested that the antibody labels a wide array of astorcytic‐lineage cells including astrocytes, astrocyte precursors, and neural stem cells. Screening a cDNA library derived from rat embryonic brain has revealed that the antibody recognizes calmodulin‐regulated spectrin‐associated protein 1 (Camsap1). Thus this antibody may provide not only a new marker to identify astrocyte‐lineage cells but also a new target molecule to elucidate the ontogeny, development, and pathophysiological functions of astrocyte‐lineage cells.
- 28 August 2008
- Published by Wiley in Journal of Neuroscience Research
- Vol. 87 (2) , 503-513
A new monoclonal antibody, A3B10, specific for astrocyte‐lineage cells recognizes calmodulin‐regulated spectrin‐associated protein 1 (Camsap1)
Recent studies of adult neurogenesis of the mammalian central nervous system have suggested unexpected plasticity and complexity of neural cell ontogenesis. Redefinition and reconstitution of cell classification and lineage relationships, especially between glial and neural precursors, are an urgent and crucial concern. In the present study, we describe a new monoclonal antibody, A3B10, which was produced by immunizing mice with the membrane fraction prepared from astrocyte‐enriched primary neural cell cultures. Immunohistochemistry of brain sections, including brains from glial fibrillary acidic protein (GFAP)‐deficient mice and primary mixed neural cell cultures, as well as immunoblot analysis and immunoelectron microscopy, have revealed that 1) A3B10 recognizes a majority of cells in ependyma in neonatal and adult rats, 2) A3B10 stains almost all GFAP+ cells and some S100β+ cells in the corpus callosum, 3) A3B10 specifically stains astrocytes in vitro in primary cultures of rat embryonic cerebral hemispheres, 4) A3B10 equally stains ependymal cells of wild‐type and GFAP‐deficient mice, and 5) A3B10 antigen might construct intermediate filament bundles with GFAP and/or vimentin. These data suggested that the antibody labels a wide array of astorcytic‐lineage cells including astrocytes, astrocyte precursors, and neural stem cells. Screening a cDNA library derived from rat embryonic brain has revealed that the antibody recognizes calmodulin‐regulated spectrin‐associated protein 1 (Camsap1). Thus this antibody may provide not only a new marker to identify astrocyte‐lineage cells but also a new target molecule to elucidate the ontogeny, development, and pathophysiological functions of astrocyte‐lineage cells.